An Update on Medtronic Options for People on Animas® Insulin Pumps

Last fall Animas® announced that they would be discontinuing the manufacture and sale of all Animas® Vibe™ and OneTouch® Ping® insulin pumps in the US and Canada. We know this news was upsetting to many of you and want you to know that you are not alone.

We’re here for you and are inspired by you. Inspired by your resilience to adapt to change while consistently balancing your own health with your personal life. That’s why our goal is to support you and earn your trust.

1. We want to make it as smooth as possible during this next year.

If you’re using an Animas pump, our priority is to make sure that you can stay on pump therapy and receive the supplies that you need. That’s why we’ve stepped up to provide service and support specifically for Animas pumps through the transition period which ends on September 30th, 2019. To minimize the impact of this change, you can call the number on the back of your current pump for anything you might need: 877.937.7867.

In the meantime, start doing your research.

After September 30th, 2019 supplies and support for Animas pumps will no longer be available from Medtronic. The risk of going back to multiple daily injections, even temporarily, is high particularly for Animas pumpers who have not begun the process of transitioning. Did you know Animas replacement pumps are not available once you are out-of-warranty? We understand this can be a difficult decision and we will be happy to discuss the Medtronic insulin pump options available to you.

2. We’re offering Animas customers the choice of either a MiniMed™ 630G insulin pump or a MiniMed™ 670G system via low to no cost programs**.

And, we’ve already heard some awesome success stories from people who have taken advantage of one of our programs. People like Matt now have the ability to focus on the moments that matter because of more Time In Range*, like spending time with his two sons and his wife.

“I work a physically demanding job with a variable schedule, so it was tough in the past to manage my diabetes regiment. The MiniMed 670G has lightened that load through its intuitive nature and on-demand information.”
–Matt S.
Former Animas pump user and current MiniMed™ 670G user

 

3. It’s your choice. We’re here to help.

While you consider your options, we also want to make sure you have discussed back-up options with your physician and received answers to any questions you may have. Our website will allow you to compare Medtronic pump features, get the answers to FAQs, and learn more about our program offerings. In the meantime, let us know if there’s anything we can do to help.

If you’d like to learn more about the pump transition programs designed for Animas customers, please call 855.322.9568 or visit www.MedtronicDiabetes.com/Animas.

 

 

*CareLink™ data from March 17, 2017 to December 31, 2017; n>15,000. Individual results may vary.
**Programs available to qualified customers with a valid prescription. Cost may vary based on warranty status, program eligibility and insurance coverage.

Important Safety Information

IMPORTANT SAFTEY INFORMATION: MINIMED™ 670G SYSTEM
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.

WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safetyinformation#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library

IMPORTANT SAFETY INFORMATION: MINIMED™ 530G SYSTEM AND MINIMED™ 630G SYSTEM
Indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus. MiniMed™ 630G system is approved for ages 14 years or older with Guardian™ Sensor 3 and MiniMed™ 530G system is approved for ages 16 years or older with Enlite™ sensor. Both systems require a prescription. Insulin infusion pumps and associated components of insulin infusion systems are limited to sale by or on the order of a physician and should only be used under the direction of a healthcare professional familiar with the risks of insulin pump therapy. Pump therapy is not recommended for people who are unwilling or unable to perform a minimum of four blood glucose tests per day. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Insulin pumps use rapid-acting insulin. If your insulin delivery is interrupted for any reason, you must be prepared to replace the missed insulin immediately. Replace the infusion set every 48–72 hours, or more frequently per your healthcare professional’s instructions. Insertion of a glucose sensor may cause bleeding or irritation at the insertion site. Consult a physician immediately if you experience significant pain or if you suspect that the site is infected. The information provided by CGM systems is intended to supplement, not replace, blood glucose information obtained using a blood glucose meter. A confirmatory fingerstick using a
CONTOUR®NEXT LINK 2.4 meter is required prior to making adjustments to diabetes therapy. Always check the pump display when using a CONTOUR®NEXT LINK 2.4 meter, to ensure the glucose result shown agrees with the glucose results shown on the meter. Do not calibrate your CGM device or calculate a bolus using a result taken from an Alternative Site (palm) or a result from a control solution test. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. The MiniMed™ 630G or MiniMed™ 530G system are not intended to be used directly for preventing or treating hypoglycemia but to suspend insulin delivery when the user is unable to respond to the Suspend on low alarm and take measures to prevent or treat hypoglycemia themselves. Therapy to prevent or treat hypoglycemia should be administered according to the recommendations of the user’s healthcare provider.
WARNING: The SmartGuard™ feature will cause the pump to temporarily suspend insulin delivery for two hours when the sensor glucose reaches a set threshold. Under some conditions of use the pump can suspend again, resulting in very limited insulin delivery. Prolonged suspension can increase the risk of serious hyperglycemia, ketosis, and ketoacidosis. Before using the SmartGuard feature, it is important to read the SmartGuard™ feature information in the User Guide and discuss proper use of the feature with your healthcare provider.
See www.medtronicdiabetes.com/importantsafetyinformation and the appropriate user guides for additional important details.

© 2018 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. All other brands are trademarks of a Medtronic company. Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.
© 2015 Animas® Corporation 2015/07
940M19360-011 30AUG2018

Print This Post Print This Post
Tags: , , , , , , , ,
Latest Comments
  1. John DeMonica
    • Karrie Hawbaker Karrie Hawbaker
  2. Kim Kearney
    • Karrie Hawbaker Karrie Hawbaker

Post A Comment

Your email address will not be published. Required fields are marked *